Carl Zeiss Meditec Stock Tumbles 13.3% on Earnings Decline

Carl Zeiss Meditec AG (AFX.DE) shares plunged 13.3% to €24.90 on the XETRA exchange today, marking one of the market’s steepest declines. The medical technology company’s stock tumbled following disappointing first-half earnings results, with revenue and profitability pressured by foreign exchange headwinds and weak China intraocular lens (IOL) sales. The company, headquartered in Jena, Germany, operates in ophthalmic devices and microsurgery segments serving hospitals and surgical centers globally. Despite the sharp selloff, management outlined an ambitious Profit Up Program targeting over €200 million in annual profit improvements by 2028-2029. AFX.DE stock now trades near 52-week lows as investors reassess the company’s near-term recovery prospects.

AFX.DE Stock Price Collapse Driven by Earnings Miss

AFX.DE stock crashed 13.3% today, erasing €3.82 per share in value as the market reacted sharply to weaker-than-expected earnings. The stock opened at €25.20 and fell to a session low of €24.46, reflecting broad-based selling pressure across the medical devices sector.

The decline extends a brutal year for shareholders. AFX.DE has lost 61.5% over the past 12 months and 77.5% over three years, signaling persistent operational challenges. The company’s market capitalization now stands at €2.22 billion, down from peaks above €5 billion just years ago. Trading volume surged to 326,297 shares, 31% above the 30-day average, indicating heavy institutional liquidation.

Earnings Pressure: FX Headwinds and China Weakness

Revenue and profitability declined in the first half of 2026, with foreign exchange fluctuations and weak China IOL sales cited as primary culprits. The company’s earnings announcement on May 12 revealed the scale of operational headwinds facing the medical technology sector.

China represents a critical market for ophthalmic devices, and softening demand there signals broader challenges in the company’s largest growth region. Currency headwinds, particularly EUR strength against emerging market currencies, compressed margins on international sales. Management expects H2 2026 to show stronger results, but investors remain skeptical given the magnitude of first-half deterioration and uncertain macroeconomic conditions ahead.

Profit Up Program Offers Long-Term Hope

Management launched an aggressive Profit Up Program targeting over €200 million in annual profit improvements by 2028-2029, with midterm EBITDA margins targeted above 15%. This restructuring initiative aims to restore profitability through operational efficiency and cost discipline across both business segments.

The program signals management confidence in the company’s long-term strategy, but near-term execution risk remains high. Investors are pricing in extended weakness before improvements materialize. Track AFX.DE on Meyka for real-time updates on restructuring progress and quarterly results.

Market Sentiment: Trading Activity and Liquidation

Technical indicators reveal heavy selling pressure with the Relative Strength Index (RSI) at 45.71, signaling oversold conditions but insufficient to trigger a rebound. The stock trades well below its 50-day moving average of €25.51 and significantly below the 200-day average of €36.24, confirming a sustained downtrend.

Volume metrics show institutional liquidation accelerating. The Money Flow Index (MFI) at 45.70 indicates weak buying interest, while the On-Balance Volume (OBV) at -2.39 million reflects consistent selling. The stock’s year-to-date decline of 36% and 52-week range of €22.62 to €65.90 underscore the severity of the selloff from pandemic-era highs.

Final Thoughts

Carl Zeiss Meditec’s 13.3% stock decline reflects real operational challenges from currency headwinds and weak regional demand. The company’s €200 million cost-cutting program by 2028-2029 offers hope, but near-term earnings remain unclear. While valuations appear reasonable at PE 15.74, the market expects continued weakness before recovery signs emerge. Investors should watch H2 2026 results for stabilization evidence. The technical setup remains bearish, and further declines are possible if management fails to deliver on cost reduction targets.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.